TY - JOUR
T1 - Role of P2Y Receptors in Platelet Extracellular Vesicle Release
AU - Gąsecka, Aleksandra
AU - Rogula, Sylwester
AU - Eyileten, Ceren
AU - Postuła, Marek
AU - Jaguszewski, Miłosz J.
AU - Kochman, Janusz
AU - Mazurek, Tomasz
AU - Nieuwland, Rienk
AU - Filipiak, Krzysztof J.
PY - 2020/9/1
Y1 - 2020/9/1
N2 - Platelet extracellular vesicles (PEVs) are potential new biomarkers of platelet activation which may allow us to predict and/or diagnose developing coronary thrombosis before myocardial necrosis occurs. The P2Y1 and P2Y12 receptors play a key role in platelet activation and aggregation. Whereas the P2Y1 antagonists are at the preclinical stage, at present, the P2Y12 antagonists are the most effective treatment strategy to prevent stent thrombosis after percutaneous coronary intervention. Despite an increasing number of publications on PEVs, the mechanisms underlying their formation, including the role of purinergic receptors in this process, remain an active research field. Here, we outline the clinical relevance of PEVs in cardiovascular disease, summarize the role and downstream signalling of P2Y receptors in platelet activation, and discuss the available evidence regarding their role in PEV formation.
AB - Platelet extracellular vesicles (PEVs) are potential new biomarkers of platelet activation which may allow us to predict and/or diagnose developing coronary thrombosis before myocardial necrosis occurs. The P2Y1 and P2Y12 receptors play a key role in platelet activation and aggregation. Whereas the P2Y1 antagonists are at the preclinical stage, at present, the P2Y12 antagonists are the most effective treatment strategy to prevent stent thrombosis after percutaneous coronary intervention. Despite an increasing number of publications on PEVs, the mechanisms underlying their formation, including the role of purinergic receptors in this process, remain an active research field. Here, we outline the clinical relevance of PEVs in cardiovascular disease, summarize the role and downstream signalling of P2Y receptors in platelet activation, and discuss the available evidence regarding their role in PEV formation.
KW - Antiplatelet therapy
KW - Clopidogrel
KW - Extracellular vesicles
KW - P2Y1 receptors
KW - P2Y12 receptors
KW - Ticagrelor
UR - http://www.scopus.com/inward/record.url?scp=85089925121&partnerID=8YFLogxK
U2 - https://doi.org/10.3390/ijms21176065
DO - https://doi.org/10.3390/ijms21176065
M3 - Review article
C2 - 32842470
SN - 1661-6596
VL - 21
SP - 1
EP - 14
JO - International journal of molecular sciences
JF - International journal of molecular sciences
IS - 17
M1 - 6065
ER -